Human IL-6 Monoclonal Antibody

$Paraformaldehyde-fixed, paraffin embedded Human liver cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 30min; Antibody incubation with IL-6 (2C6) Monoclonal Antibody, Unconjugated (bsm-10807M) at 1:400 overnight at 4\u00b0C, DAB staining.$

Paraformaldehyde-fixed, paraffin embedded Human liver cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 30min; Antibody incubation with IL-6 (2C6) Monoclonal Antibody, Unconjugated (bsm-10807M) at 1:400 overnight at 4\u00b0C, DAB staining.

$HUVEC (H) cells were treated with or without LPS (0.5 \u03bcg\/ml\uff0c24h) and Brefeldin A (300 ng\/ml\uff0c20h) , 25 \u03bcg total protein per lane of cell lysates (see on figure) probed with human IL-6 monoclonal antibody, unconjugated (bsm-10807M) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.$

HUVEC (H) cells were treated with or without LPS (0.5 \u03bcg\/ml\uff0c24h) and Brefeldin A (300 ng\/ml\uff0c20h) , 25 \u03bcg total protein per lane of cell lysates (see on figure) probed with human IL-6 monoclonal antibody, unconjugated (bsm-10807M) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.

$Paraformaldehyde-fixed, paraffin embedded Human Ovarian Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with human IL-6 Monoclonal Antibody, Unconjugated(bsm-10807M) at 1:200 overnight at 4\u00b0C, followed by conjugation to the SP Kit (Mouse, sp-0024) and DAB (C-0010) staining.$

Paraformaldehyde-fixed, paraffin embedded Human Ovarian Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with human IL-6 Monoclonal Antibody, Unconjugated(bsm-10807M) at 1:200 overnight at 4\u00b0C, followed by conjugation to the SP Kit (Mouse, sp-0024) and DAB (C-0010) staining.

Applications

WB
IHC-P
IHC-F
IF(IHC-P)

Reactivity

Human

Overview
Catalog #	bsm-10807m-100ul
Product Name	Human IL-6 Monoclonal Antibody
Applications	WB, IHC-P, IHC-F, IF(IHC-P)
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Mouse
Source	Recombinant human IL-6 corresponding to 30-212/212aa (C-6x His-Tag)
Clonality	Monoclonal
Clone #	2C6
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein G.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Store at -20°C for 12 months.
Target
Gene ID	3569
Swiss Prot	P05231
Subcellular location	Secreted
Synonyms	Interleukin BSF 2; B cell differentiation factor; B cell stimulatory factor 2; BSF 2; BSF2; CDF; CTL differentiation factor; Cytotoxic T cell differentiation factor; Hepatocyte stimulating factor; HGF; HPGF; HSF; Hybridoma growth factor; Hybridoma plasmacytoma growth factor; IFNB2; IL 6; IL6 protein; Interferon beta 2; Interleukin 6 (interferon beta 2); Interleukin 6; Interleukin-6; Interleukin6; IL6_HUMAN.
Background	This gene encodes a cytokine that functions in inflammation and the maturation of B cells. In addition, the encoded protein has been shown to be an endogenous pyrogen capable of inducing fever in people with autoimmune diseases or infections. The protein is primarily produced at sites of acute and chronic inflammation, where it is secreted into the serum and induces a transcriptional inflammatory response through interleukin 6 receptor, alpha. The functioning of this gene is implicated in a wide variety of inflammation-associated disease states, including suspectibility to diabetes mellitus and systemic juvenile rheumatoid arthritis. [provided by RefSeq, Jun 2011].
Application Dilution
WB	1:2000-20000
IHC-P	IHC-P1:200-800
IHC-F	IHC-F1:200-800
IF(IHC-P)	IFIHC-P1:200-800